StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the stock.
Separately, Needham & Company LLC reaffirmed a buy rating and set a $4.25 price objective on shares of OncoCyte in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $4.06.
Read Our Latest Analysis on OCX
OncoCyte Price Performance
OncoCyte Company Profile
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Featured Articles
- Five stocks we like better than OncoCyte
- Breakout Stocks: What They Are and How to Identify Them
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- The Significance of Brokerage Rankings in Stock Selection
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Where Do I Find 52-Week Highs and Lows?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.